THE EU JOINT HEALTH TECHNOLOGY ASSESSMENT: A FIT FOR PURPOSE JCA?

This panel will delve into the anticipated impact of the JCA on the ATMP sector in Europe in 2025 and beyond. Speakers will examine strategies for crafting compelling evidence for regulators and HTAs, assess if the European HTA coordination is going to simplify or complicate things, and scrutinize whether national Pricing and Reimbursement bodies will effectively access the necessary information from the JCA.
Moderator:
Miguel Forte, M.D., Ph.D., CEO, Kiji Therapeutics
Speakers:
Alessandro Aiuti, M.D., Ph.D., Deputy Director Clinical Research, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan; Professor of Pediatrics, Vita-Salute San Raffaele University, Milan
Loris Brunetta, Founding Board Member, Thalassaemia International Federation (TIF)
Rui Ivo, Pharm.D., President of National Authority of Medicines and Healthcare Products (INFARMED), Portugal
Marco Marchetti, M.D., Director, Health Technology Assessment, AGENAS
Francis Pang, Senior Vice President, Global Market Access and Geographic Expansion, Orchard Therapeutics